Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cardiovascular Drug Interactions With Nirmatrelvir/Ritonavir in Patients With COVID-19
Sonu Abraham, Anju Nohria, Tomas G. Neilan, et al.
Journal of the American College of Cardiology (2022) Vol. 80, Iss. 20, pp. 1912-1924
Open Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Potential herb–drug interactions between anti-COVID-19 drugs and traditional Chinese medicine
Ling Ye, Shicheng Fan, Pengfei Zhao, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 9, pp. 3598-3637
Open Access | Times Cited: 26
Clinical Risk and Outpatient Therapy Utilization for COVID-19 in the Medicare Population
Andrew D. Wilcock, Stephen M. Kissler, Ateev Mehrotra, et al.
JAMA Health Forum (2024) Vol. 5, Iss. 1, pp. e235044-e235044
Open Access | Times Cited: 8
Atherosclerosis, Cardiovascular Disease, and COVID-19: A Narrative Review
Carles Vilaplana-Carnerero, Maria Giner‐Soriano, Ángela Domı́nguez, et al.
Biomedicines (2023) Vol. 11, Iss. 4, pp. 1206-1206
Open Access | Times Cited: 14
Paxlovid use is associated with lower risk of cardiovascular diseases in COVID-19 patients with autoimmune rheumatic diseases: a retrospective cohort study
Weijie Wang, Yu‐Hsun Wang, Ching‐Hua Huang, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 4
Role of Cytochrome P450 2C9 in COVID-19 Treatment: Current Status and Future Directions
Sharoen Yu Ming Lim, Basel Al Bishtawi, Willone Lim
European Journal of Drug Metabolism and Pharmacokinetics (2023) Vol. 48, Iss. 3, pp. 221-240
Open Access | Times Cited: 10
Cardiac Arrhythmias and Autonomic Dysfunction Associated With COVID-19: A Scientific Statement From the American Heart Association
Rakesh Gopinathannair, Brian Olshansky, Mina K. Chung, et al.
Circulation (2024) Vol. 150, Iss. 21
Closed Access | Times Cited: 2
Nirmatrelvir and ritonavir combination: an antiviral therapy for COVID-19
Gangireddy Navitha Reddy, Akanksha Jogvanshi, Sana Naikwadi, et al.
Expert Review of Anti-infective Therapy (2023) Vol. 21, Iss. 9, pp. 943-955
Closed Access | Times Cited: 7
Efficacy and Safety of Adintrevimab (ADG20) for the Treatment of High-Risk Ambulatory Patients With Mild or Moderate COVID-19: Results From a Phase 2/3, Randomized, Placebo-Controlled Trial (STAMP) Conducted During Delta Predominance and Early Emergence of Omicron
Michael G. Ison, Myra W. Popejoy, Nikolay Evgeniev, et al.
Open Forum Infectious Diseases (2023)
Open Access | Times Cited: 6
Nirmatrelvir-Ritonavir for Acute COVID-19 in Patients With Cardiovascular Disease and Postacute Sequelae of SARS-CoV-2 Infection
Rushin Patel, Sourbha S. Dani, Sumanth Khadke, et al.
JACC Advances (2024) Vol. 3, Iss. 6, pp. 100961-100961
Open Access | Times Cited: 1
Efficacy of COVID-19 Oral antivirals in hospitalised oldest-old with high morbidity burden: a target trial emulation study
Francisco Tsz Tsun Lai, Boyuan Wang, Cuiling Wei, et al.
Age and Ageing (2024) Vol. 53, Iss. 8
Closed Access | Times Cited: 1
Interactions of warfarin with COVID-19 vaccine/drugs, monoclonal antibodies, and targeted anticancer agents from real-world data mining
Yan Gao, Qingsong Huang, Jun Li, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Appraisal of evidence reliability and applicability of Paxlovid as treatment for SARS‐COV‐2 infection: A systematic review
Changtai Zhu, Jianyun Yin, Xiaohua Chen, et al.
Reviews in Medical Virology (2023) Vol. 33, Iss. 6
Closed Access | Times Cited: 3
2023 Chinese expert consensus on the impact of COVID-19 on the management of cardiovascular diseases
Feng Bai, Jun Pu, Wenliang Che, et al.
Cardiology Plus (2023)
Open Access | Times Cited: 2
Design, synthesis and biological evaluation of chalcone derivatives as potent and orally active hCYP3A4 inhibitors
Shiwei Lü, Feng Zhang, Jia-Hao Gong, et al.
Bioorganic & Medicinal Chemistry Letters (2023) Vol. 95, pp. 129435-129435
Closed Access | Times Cited: 2
Perfil de seguridad de nirmatrelvir-ritonavir: evidencia de eventos adversos por interacciones farmacológicas
Álvaro González‐Gómez, José Manuel Caro‐Teller, Iván Gonzalez-Barrios, et al.
Farmacia Hospitalaria (2023) Vol. 48, Iss. 2, pp. 70-74
Open Access | Times Cited: 2
Absolute Risk Reductions in COVID-19 Antiviral Medication Clinical Trials
Ronald B. Brown
Pharmacoepidemiology (2023) Vol. 2, Iss. 1, pp. 98-105
Open Access | Times Cited: 2
Drug-drug interaction between danshensu and irbesartan and its potential mechanism
Yuexia Li, Liheng Liu
Xenobiotica (2024) Vol. 54, Iss. 4, pp. 211-216
Closed Access
Discovery of macrocyclic covalent inhibitors for severe acute respiratory syndrome coronavirus 2 3CL protease
Xiubo Tang, Kai Hou, Xiao‐Wu Chen, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 111, pp. 117846-117846
Closed Access
Cardiovascular Drug Interactions with Nirmatrelvir/Ritonavir for COVID-19: Considerations for Daily Practice
Andrea Di Lenarda, Nicola Ferri, Massimiliano Lanzafame, et al.
European Cardiology Review (2024) Vol. 19
Open Access
Evaluation of the drug-drug interactions management system for appropriate use of nirmatrelvir/ritonavir: a retrospective observational study
Takeshi Tomida, Takeshi Kimura, Kazuhiro Yamamoto, et al.
Journal of Pharmaceutical Health Care and Sciences (2024) Vol. 10, Iss. 1
Open Access
Prevalence of Potential Drug Interactions With Direct-Acting Antivirals for COVID-19 Among Hospitalized Patients
Essy Mozaffari, Aastha Chandak, Andrew Ustianowski, et al.
Clinical Therapeutics (2024)
Open Access
Outcomes and Healthcare Resource Utilization in Patients with COVID-19 Treated with Nirmatrelvir–Ritonavir: Real-World Data Analysis
Clara Weil, Lilac Tene, Gabriel Chodick, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 20, pp. 6091-6091
Open Access
Emerging therapeutic options
Anu Mariam Saji, Sonu Abraham, Sarju Ganatra
Elsevier eBooks (2024), pp. 257-274
Closed Access
Evaluation of drug-drug interactions in patients with cardiovascular disease and type 2 diabetes while receiving nirmatrelvir/ritonavir
Zuzana Mačeková, Veronika Tomášová, Katarína Pajerová, et al.
Klinická farmakologie a farmacie (2024) Vol. 38, Iss. 3, pp. 92-99
Open Access
Supratherapeutic INR During Treatment With Nirmatrelvir/Ritonavir and Warfarin and Acute Illness With COVID-19: A Case Report
Caitlin Dowd-Green, Dannielle Brown, A. Justine Wilson, et al.
Journal of Pharmacy Practice (2024) Vol. 37, Iss. 6, pp. 1414-1418
Closed Access
Page 1 - Next Page

Scroll to top